4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Die 4SC AG (4SC, FSE Prime Standard: VSC), ein Biotech-Unternehmen, das das Leben von Patienten mit kutanem T-Zell-Lymph…
Die 4SC AG (4SC, FSE Prime Standard: VSC), ein Biotech-Unternehmen, das das Leben von Patienten mit kutanem T-Zell-Lymph…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
Die Europäische Arzneimittelbehörde (EMA) hat dem Antrag von 4SC auf sog. Orphan Drug Designation für Resminostat (K…
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survi…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…
4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2022, presenting all material developments up…
Die 4SC AG (4SC, FWB Prime Standard: VSC) hat heute den Halbjahresbericht zum 30. Juni 2022 veröffentlicht, in der sie d…